Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions

Objectives: We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small cell lung cancer (NSCLC) and study their correlation to somatic mutations and clinical outcomes. Materials and Methods: Cells were immunomagnetically separated from samples of pleural effusion in patients with NSCLC. p-AKT, p-S6K and p-GSK3β levels were quantified by ELISA; targeted next-generation sequencing was used to characterise mutations in 26 genes. Results: It was possible to quantify phosphoproteins in cells isolated from 38/43 pleural effusions. There was a significant correlation between p-AKT and p-S6K levels [r = 0.85 (95% confidence interval 0.73-0.92), p < 0.0001], but not p-AKT and p-GSK3β levels [r = 0.19 (95% confidence interval -0.16 to 0.5), p = 0.3]. A wide range of mutations was described and p-S6K was higher in samples that harboured at least one mutation compared to those that did not (p = 0.03). On multivariate analysis, p-S6K levels were significantly associated with poor survival (p < 0.01). Conclusion: Our study has shown a correlation between p-AKT levels and p-S6K, but not GSK3β, suggesting differences in regulation of the distal PI3K pathway by AKT. Higher p-S6K levels were associated with adverse survival, making it a critically important target in NSCLC.

[1]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[2]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[3]  E. Smit,et al.  Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. , 2015, Lung cancer.

[4]  S. Elledge,et al.  RNAi-based functional selection identifies novel cell migration determinants dependent on PI3K and AKT pathways , 2014, Nature Communications.

[5]  Zhi-qin Fu,et al.  Prognostic value of phospho‐Akt in patients with non‐small cell lung carcinoma: A meta‐analysis , 2014, International journal of cancer.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[7]  Yi-long Wu,et al.  Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay , 2014, Chinese journal of cancer.

[8]  C. Huang,et al.  Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts , 2014, British Journal of Cancer.

[9]  P. Brauns-Schubert,et al.  GSK-3 – at the crossroads of cell death and survival , 2014, Journal of Cell Science.

[10]  Haiquan Chen,et al.  PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup , 2014, PloS one.

[11]  I. Wistuba,et al.  The evolving genomic classification of lung cancer , 2013, The Journal of pathology.

[12]  G. Mills,et al.  A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. , 2014, Cancer research.

[13]  Z. Qiu,et al.  The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.

[14]  G. Giaccone,et al.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. , 2013, The Lancet. Oncology.

[15]  D. Kwiatkowski,et al.  Molecular Dissection of AKT Activation in Lung Cancer Cell Lines , 2013, Molecular Cancer Research.

[16]  G. Hampton,et al.  Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models , 2012, Clinical Cancer Research.

[17]  M. Gore,et al.  The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer , 2012, Molecular Cancer Therapeutics.

[18]  M. Ceccarelli,et al.  Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase , 2012, PloS one.

[19]  A. Wozniak,et al.  Clinical presentation of non-small cell carcinoma of the lung , 2012 .

[20]  M. Gore,et al.  The Association of PI 3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer , 2012 .

[21]  M. Ladanyi,et al.  Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling , 2011, Molecular Cancer Therapeutics.

[22]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[23]  Dong Sun Kim,et al.  PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. , 2010, Lung cancer.

[24]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[25]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[26]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[27]  J. Heffner,et al.  Diagnosis and management of malignant pleural effusions , 2007, Respirology.

[28]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[29]  Jing Fu,et al.  [Phophorylated Akt protein expression in non-small cell lung cancer]. , 2007, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[30]  H. Sasaki,et al.  PIK3CA gene amplification in Japanese non-small cell lung cancer. , 2007, Lung cancer.

[31]  H. Sugimura,et al.  PIK3CA mutation and amplification in human lung cancer , 2007, Pathology international.

[32]  C. Miller,et al.  PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. , 2007, Oncology reports.

[33]  S. Steinberg,et al.  Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. , 2007, Lung cancer.

[34]  M. Meyerson,et al.  Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. , 2006, Cancer research.

[35]  R. Guo,et al.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.

[36]  H. Wu,et al.  PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer , 2006, Oncogene.

[37]  H. Wu,et al.  PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. , 2006, Oncogene.

[38]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[39]  K. O'Byrne,et al.  Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[40]  F. Cappuzzo,et al.  Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.

[41]  J. Jett,et al.  Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  R. Ramlau,et al.  Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Won Sang Park,et al.  Non‐small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[44]  D. Rimm,et al.  Use of magnetic enrichment for detection of carcinoma cells in fluid specimens , 2002, Cancer.

[45]  E. Raymond,et al.  Detection of circulating carcinoma cells by telomerase activity , 2001, British Journal of Cancer.

[46]  M. Wick,et al.  Fixation and Epitope Retrieval in Diagnostic Immunohistochemistry: A Concise Review with Practical Considerations , 2000, Applied immunohistochemistry & molecular morphology : AIMM.